NewYork-Presbyterian/Columbia University Irving Medical Center, also known as the Columbia University Irving Medical Center, is an academic medical center and the largest campus of NewYork-Presbyterian Hospital.

During the past decade, Columbia University Medical Center conducted 897 clinical trials. In the 10-year time frame, 897 clinical trials started and 451 clinical trials were completed, i.e. on average, 50.3% percent of trials that started reached the finish line to date. In the past 5 years, 295 clinical trials started and 214 clinical trials were completed. i.e. 72.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Columbia University Medical Center" #1 sponsor was "Columbia University" with 404 trials, followed by "Hoffmann-La Roche" with 31 trials sponsored, "National Cancer Institute (NCI)" with 31 trials sponsored, "Bristol-Myers Squibb" with 26 trials sponsored and "Children's Oncology Group" with 26 trials sponsored. Other sponsors include 1062 different institutions and companies that sponsored additional 551 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Columbia University Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 62 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 62 trials as a collaborator, "Columbia University" with 44 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 42 trials as a collaborator and "National Institute on Aging (NIA)" with 30 trials as a collaborator. Other collaborators include 1106 different institutions and companies that were collaborators in the rest 566 trials.

According to Clinical.Site data, the most researched conditions in "Columbia University Medical Center" are "Coronary Artery Disease" (35 trials), "Breast Cancer" (29 trials), "Cystic Fibrosis" (26 trials), "Stroke" (24 trials) and "Asthma" (22 trials). Many other conditions were trialed in "Columbia University Medical Center" in a lesser frequency.

Most popular intervention types in "Columbia University Medical Center" are "Drug" (927 trials), "Other" (233 trials), "Device" (230 trials), "Biological" (139 trials) and "Procedure" (122 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (204 trials), "Cyclophosphamide" (26 trials), "Nivolumab" (23 trials), "Gemcitabine" (22 trials) and "Carboplatin" (19 trials). Other intervention names were less common.

The vast majority of trials in "Columbia University Medical Center" are 1400 trials for "All" genders, 146 trials for "Female" genders and 36 trials for "Male" genders.

Currently, there are 520 active trials in "Columbia University Medical Center". 15 are not yet recruiting, 303 are recruiting, 187 are Active, not recruiting, and 15 are Enrolling by invitation. In total, there were 792 completed trials in Columbia University Medical Center, 5 suspended trials, and 196 terminated clinical trials to date.

Out of the total trials that were conducted in Columbia University Medical Center, 252 "Phase 1" clinical trials were conducted, 447 "Phase 2" clinical trials and 357 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 71 trials, and there were also 336 trials that are defined as “Not Applicable".